

March 07, 2023

To whom it may concern

**Nissan Chemical's "prevelex® CC1" contributed to manufacturing
allogeneic induced pluripotent stem cells (iPSCs)- derived cardiomyocyte spheroids**

~ Heartseed announced the first patient dosed in the Phase I/II LAPiS study
with HS-001 – a cell therapy designed to restore heart function
in people with advanced heart failure ~

Nissan Chemical Corporation (hereinafter "Nissan Chemical") announces that Nissan Chemical has been providing Heartseed Inc. (hereinafter "Heartseed") with prevelex® CC1, a coating material, for Heartseed's production of allogeneic iPSC-derived cardiomyocyte spheroids.

Heartseed announced on February 10th, 2023 that Heartseed had successfully dosed the first patient in a phase 1/2 clinical trial (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. prevelex® CC1 was used for the production of iPSC-derived cardiomyocyte spheroids for the clinical trial.

The prevelex® series developed by Nissan Chemical are anti-adhesion coating materials for biomaterials, which can be used from research to clinical application.

prevelex® CC1 was used for the production of allogeneic iPSC-derived cardiomyocyte spheroids for Heartseed's clinical trial. As a manufacturing-process material, prevelex® CC1 ensures the high quality and safety standards required in the field of cell therapy and other applications. prevelex® CC1 has a high cell adhesion inhibitory effect and can be used for spheroid formation.

Nissan Chemical, in collaboration with Heartseed, will continue to work on the development of technologies for the mass production of cardiomyocyte spheroids by leveraging the expertise of both companies.

<About Nissan Chemical Corporation>

Nissan Chemical Corporation's vision is to become a corporate group that contributes to the protection of the global environment, the wellbeing of humanity and valued by society. In that aim the Planning and Development Division's mission is to create new products and businesses in the following domains; Information and Communication, Environment and Energy and Health Care. Products developed for these domains will utilize highly novel technologies to meet market and societal needs. For more information, please visit <https://www.nissanchem.co.jp/>

<About Heartseed>

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production. Heartseed has received many awards. For more information, please visit Heartseed's website.

- <https://heartseed.jp/en/index.html>
- <https://heartseed.jp/en/news/content.html>

Contact information for inquires on the above

Nissan Chemical Corporation Corporate Planning Department Public Relations Office E-mail: pr_cpd.nissanchem.co.jp
